Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA)

Charles Schwab Investment Management Inc. increased its position in Savara Inc (NASDAQ:SVRA) by 5.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 963,821 shares of the company’s stock after purchasing an additional 52,204 shares during the period. Charles Schwab Investment Management Inc. owned 0.56% of Savara worth $2,959,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in shares of Savara in the 3rd quarter worth approximately $67,000. BNP Paribas Financial Markets increased its position in Savara by 258.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after buying an additional 18,534 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock valued at $112,000 after buying an additional 4,732 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Savara by 14.0% in the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after acquiring an additional 6,330 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Savara in the third quarter worth $174,000. Institutional investors own 87.93% of the company’s stock.

Savara Trading Up 3.0 %

Shares of NASDAQ:SVRA opened at $2.78 on Friday. Savara Inc has a 1 year low of $2.26 and a 1 year high of $5.34. The stock’s fifty day moving average price is $2.72 and its 200-day moving average price is $3.27. The company has a market cap of $477.10 million, a P/E ratio of -6.47 and a beta of 0.60. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SVRA shares. Wells Fargo & Company initiated coverage on Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price target for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Savara in a report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.83.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.